Craig W. Lindsley

30.9k total citations · 1 hit paper
619 papers, 21.6k citations indexed

About

Craig W. Lindsley is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Craig W. Lindsley has authored 619 papers receiving a total of 21.6k indexed citations (citations by other indexed papers that have themselves been cited), including 441 papers in Molecular Biology, 306 papers in Cellular and Molecular Neuroscience and 112 papers in Organic Chemistry. Recurrent topics in Craig W. Lindsley's work include Neuroscience and Neuropharmacology Research (270 papers), Receptor Mechanisms and Signaling (249 papers) and Ion channel regulation and function (76 papers). Craig W. Lindsley is often cited by papers focused on Neuroscience and Neuropharmacology Research (270 papers), Receptor Mechanisms and Signaling (249 papers) and Ion channel regulation and function (76 papers). Craig W. Lindsley collaborates with scholars based in United States, Australia and United Kingdom. Craig W. Lindsley's co-authors include P. Jeffrey Conn, Colleen M. Niswender, Carrie K. Jones, Corey R. Hopkins, Thomas M. Bridges, Arthur Christopoulos, H. Alex Brown, Zhijian Zhao, William Leister and J. Scott Daniels and has published in prestigious journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Craig W. Lindsley

602 papers receiving 21.2k citations

Hit Papers

Allosteric modulators of GPCRs: a novel approach for the ... 2008 2026 2014 2020 2008 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
    2008 844 citations P. Jeffrey Conn, Arthur Christopoulos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Craig W. Lindsley United States 72 14.1k 9.6k 3.9k 1.4k 1.4k 619 21.6k
Jonathan A. Javitch United States 90 16.9k 1.2× 15.0k 1.6× 764 0.2× 1.3k 0.9× 1.2k 0.9× 272 24.7k
Daniël Hoyer Switzerland 83 13.9k 1.0× 13.3k 1.4× 2.4k 0.6× 1.8k 1.2× 321 0.2× 371 26.6k
Adriaan P. IJzerman Netherlands 66 13.9k 1.0× 5.7k 0.6× 3.1k 0.8× 935 0.7× 2.6k 1.9× 470 21.3k
Rob Leurs Netherlands 71 10.9k 0.8× 3.8k 0.4× 1.8k 0.5× 813 0.6× 1.2k 0.9× 443 19.1k
Jean‐Philippe Pin France 84 18.5k 1.3× 19.7k 2.1× 744 0.2× 798 0.6× 922 0.7× 301 26.9k
Michael Spedding France 65 11.7k 0.8× 8.4k 0.9× 750 0.2× 2.5k 1.8× 902 0.7× 231 24.4k
Stephen J. Haggarty United States 56 13.4k 1.0× 2.5k 0.3× 1.5k 0.4× 1.2k 0.9× 1.6k 1.2× 140 19.0k
Henry A. Lester United States 86 19.0k 1.4× 12.5k 1.3× 1.1k 0.3× 1.3k 0.9× 234 0.2× 371 25.0k
Victor J. Hruby United States 80 19.5k 1.4× 9.3k 1.0× 6.7k 1.7× 964 0.7× 838 0.6× 858 32.2k
Roger K. Sunahara United States 59 15.7k 1.1× 10.2k 1.1× 443 0.1× 784 0.5× 1.0k 0.8× 132 20.2k

Countries citing papers authored by Craig W. Lindsley

Since Specialization
Citations

This map shows the geographic impact of Craig W. Lindsley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig W. Lindsley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig W. Lindsley more than expected).

Fields of papers citing papers by Craig W. Lindsley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig W. Lindsley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig W. Lindsley. The network helps show where Craig W. Lindsley may publish in the future.

Co-authorship network of co-authors of Craig W. Lindsley

This figure shows the co-authorship network connecting the top 25 collaborators of Craig W. Lindsley. A scholar is included among the top collaborators of Craig W. Lindsley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig W. Lindsley. Craig W. Lindsley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lazarenko, Roman M., Liangping Li, Emily Days, et al.. (2025). Characterization of Next-Generation Inhibitors for the Inward-Rectifier Potassium Channel Kir2.1: Discovery of VU6080824. ACS Medicinal Chemistry Letters. 16(9). 1762–1771.
2.
Mobbs, Jesse I., Jinan Wang, Patrick R. Gentry, et al.. (2025). Cryo-EM reveals an extrahelical allosteric binding site at the M5 mAChR. Nature Communications. 16(1). 7046–7046.
3.
Spearing, Paul K., Sichen Chang, Analisa D. Thompson, et al.. (2025). Discovery of a Novel sp3-Rich M1 Positive Allosteric Modulators (PAMs) Chemotype via Scaffold Hopping. ACS Medicinal Chemistry Letters. 16(7). 1231–1238.
4.
Urata, H, Masaya Kokubo, Takahiro Mori, et al.. (2025). Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator In Vivo Tool Compound. ACS Chemical Neuroscience. 16(5). 960–967. 1 indexed citations
5.
Engers, Julie L., Aaron M. Bender, Jonathan W. Dickerson, et al.. (2024). Discovery of VU6007496: Challenges in the Development of an M1 Positive Allosteric Modulator Backup Candidate. ACS Chemical Neuroscience. 15(18). 3421–3433. 3 indexed citations
6.
7.
Foster, Daniel J., et al.. (2022). mGlu1-mediated restoration of prefrontal cortex inhibitory signaling reverses social and cognitive deficits in an NMDA hypofunction model in mice. Neuropsychopharmacology. 47(10). 1826–1835. 5 indexed citations
8.
Thomsen, Morgane, Jill R. Crittenden, Craig W. Lindsley, & Ann M. Graybiel. (2022). Effects of acute and repeated administration of the selective M 4 PAM VU0152099 on cocaine versus food choice in male rats. Addiction Biology. 27(2). e13145–e13145. 9 indexed citations
9.
Lin, Xin, Nicole M. Fisher, Shalini Dogra, et al.. (2022). Differential activity of mGlu7 allosteric modulators provides evidence for mGlu7/8 heterodimers at hippocampal Schaffer collateral-CA1 synapses. Journal of Biological Chemistry. 298(10). 102458–102458. 13 indexed citations
10.
Lindsley, Craig W., et al.. (2021). Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG. Frontiers in Neuroscience. 15. 700822–700822. 10 indexed citations
11.
Barbaro, Lisa, Alice L. Rodriguez, Jonathan W. Dickerson, et al.. (2021). Discovery of “Molecular Switches” within a Series of mGlu5 Allosteric Ligands Driven by a “Magic Methyl” Effect Affording Both PAMs and NAMs with In Vivo Activity, Derived from an M1 PAM Chemotype. SHILAP Revista de lepidopterología. 1(1). 21–30. 3 indexed citations
12.
Walker, Leigh C., Nicola A. Chen, Patricia Rueda, et al.. (2020). Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry. 88(12). 898–909. 30 indexed citations
13.
Gregory, Karen J., Thomas M. Bridges, Rocco G. Gogliotti, et al.. (2019). In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. ACS Pharmacology & Translational Science. 2(6). 442–452. 6 indexed citations
14.
Vuckovic, Ziva, Patrick R. Gentry, Kunio Hirata, et al.. (2019). Crystal structure of the M 5 muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences. 116(51). 26001–26007. 53 indexed citations
15.
Smith, Emery, Peter Chase, Colleen M. Niswender, et al.. (2015). Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). SLAS DISCOVERY. 20(7). 858–868. 25 indexed citations
16.
Engers, Darren W., Audrey Y. Frist, Craig W. Lindsley, Charles C. Hong, & Corey R. Hopkins. (2013). Synthesis and structure–activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: The discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorganic & Medicinal Chemistry Letters. 23(11). 3248–3252. 71 indexed citations
17.
Bridges, Thomas M., Evan P. Lebois, Corey R. Hopkins, et al.. (2010). The antipsychotic potential of muscarinic allosteric modulation. Drug News & Perspectives. 23(4). 229–229. 50 indexed citations
18.
Miller, Todd W., Marianela Pérez-Torres, Archana Narasanna, et al.. (2009). Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. Cancer Research. 69(10). 4192–4201. 141 indexed citations
19.
Bridges, Thomas M., Joy E. Marlo, Colleen M. Niswender, et al.. (2009). Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N -Benzyl Isatins. Journal of Medicinal Chemistry. 52(11). 3445–3448. 88 indexed citations
20.
Jones, Carrie K., Fangfang Xiang, Andrew K. Jones, et al.. (2008). Novel allosteric modulators of metabotropic glutamate receptors subtypes 2 and 5 for the treatment of schizophrenia. Neuropharmacology. 55. 603–603. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan A. Javitch Breakdown of academic impact, for papers by Daniël Hoyer Breakdown of academic impact, for papers by Adriaan P. IJzerman Breakdown of academic impact, for papers by Rob Leurs Breakdown of academic impact, for papers by Jean‐Philippe Pin Breakdown of academic impact, for papers by Michael Spedding Breakdown of academic impact, for papers by Stephen J. Haggarty Breakdown of academic impact, for papers by Henry A. Lester Breakdown of academic impact, for papers by Victor J. Hruby Breakdown of academic impact, for papers by Roger K. Sunahara
Rankless by CCL
2026